IMVAMUNE Publications

Zitzmann-Roth E-M, von Sonnenburg F, de la Motte S, Arndtz-Wiedemann N, von Krempelhuber A, Uebler N, et al.

Cardiac Safety of Modified Vaccinia Ankara for Vaccination against Smallpox in a Young, Healthy Study Population

PLoS ONE. 2015; 10(4):e0122653. doi:10.1371/journal.pone.0122653
Frey SE, Winokur PL . et al.

Safety and immunogenicity of IMVAMUNE(®) smallpox vaccine using different strategies for a post event scenario

Vaccine. 2013 Jun 24;31(29):3025-33. doi: 10.1016/j.vaccine.2013.04.050.
Hatch GJ, Graham VA, et al.

Assessment of the Protective Effect of Imvamune and Acam2000 Vaccines against Aerosolized Monkeypox Virus in Cynomolgus Macaques.

J Virol. 2013 Jul;87(14):7805-15. doi: 10.1128/JVI.03481-12.
Townsend MB, Keckler MS, et al.:

Humoral immunity to smallpox vaccines and monkeypox virus challenge: proteomic assessment and clinical correlations.

J Virol. 2013 Jan;87(2):900-11. doi: 10.1128/JVI.02089-12.
Walsh SR, Wilck MB, et al.:

Safety and immunogenicity of modified vaccinia ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.

J Infect Dis. 2013 Jun 15;207(12):1888-97. doi: 10.1093/infdis/jit105.
Keckler MS, Carroll DS, et al.:

Establishment of the black-tailed prairie dog (Cynomys ludovicianus) as a novel animal model for comparing smallpox vaccines administered preexposure in both high- and low-dose monkeypox virus challenges.

J Virol. 2011 Aug;85(15):7683-98. doi: 10.1128/JVI.02174-10.
von Krempelhuber A, Vollmar J, et al.

A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.

Vaccine. 2010 Feb 3;28(5):1209-16. doi: 10.1016/j.vaccine.2009.11.030.
Wolff MW, Siewert C, et al.

Capturing of cell culture-derived modified Vaccinia Ankara virus by ion exchange and pseudo-affinity membrane adsorbers.

Biotechnol Bioeng. 2010 Mar 1;105(4):761-9. doi: 10.1002/bit.22595.
Garza NL, Hatkin JM, et al.

Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model.

Vaccine. 2009 Sep 4;27(40):5496-504. doi: 10.1016/j.vaccine.2009.06.105.
Kennedy JS, Greenberg RN

IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine.

Expert Rev Vaccines. 2009 Jan;8(1):13-24. doi: 10.1586/14760584.8.1.13.
Sano J, Chaitman BR, et al.

Electrocardiography screening for cardiotoxicity after modified Vaccinia Ankara vaccination.

Am J Med. 2009 Jan;122(1):79-84. doi: 10.1016/j.amjmed.2008.07.025.
Jones T

IMVAMUNE, an attenuated modified vaccinia Ankara virus vaccine for smallpox infection.

Curr Opin Mol Ther. 2008 Aug;10(4):407-17.
Frey SE, Newman FK, et al.

Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge.

Vaccine. 2007 Dec 12;25(51):8562-73.
Vollmar J, Arndtz N, et al.

Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine.

Vaccine. 2006 Mar 15;24(12):2065-70.